Hong Kong – Chronic disease scheme aids citizens
Chronic disease scheme aids citizens
************************************
The Chronic Disease Co-Care Pilot Scheme has achieved its goal of preventing diseases before occurrence and managing them at an early stage. This is why participating doctors are urging those eligible to undergo screening.
Apart from interviewing a family doctor and a district health centre representative to understand the effectiveness of the scheme, news.gov.hk spoke with one participant who shares how she manages her chronic disease.
The story is available at www.news.gov.hk/eng/feature/ today (January 21) in text and video format.
Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference, in San Francisco, California and virtually. Summary of Presentations in the Scientific Session featuring Lecanemab at CTAD Design of Clarity AD Study Eisai’s Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early AD (lecanemab group: 898 placebo group: 897) at 235 sites in North America, Europe, and Asia. The participants were randomized 1:1 to receive either placebo or lecanemab 10-mg/kg IV biweekly, and the randomization was stratified according to clinical subgroup (MCI due to AD or mild AD), presence or absence of concomitant approved AD symptomatic medication at baseline (e.g., acetylcholinesterase inhibitors, memantine, or both), ApoE4 status and geographical region. Eligibility criteria allowed patients with a broad range of comorbidities/comedications, including but not limited to hypertension, diabetes, heart disease, obesity, renal disease and anti-coagulants. As a result of Eisai’s recruitment strategy of diversity in the Clarity AD study, 4.5% and 22.5% of the randomized participants in the U.S. were Black and Hispanic, respectively. The primary endpoint was change from baseline at 18 months in the CDR-SB1 (Clinical Dementia Rating Sum of Boxes), the global cognitive and functional scale, and key secondary endpoints were the change from baseline at 18 months in amyloid Positron Emission Tomography (PET) using Centiloids, AD Assessment Scale – Cognitive Subscale 14 (ADAS-Cog142), AD Composite Score (ADCOMS3) and AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL4). In addition, longitudinal changes in brain tau pathology as measured by tau PET (n=257) and cerebrospinal fluid (CSF) biomarkers of AD pathology (n=281) were evaluated in optional sub-studies. Efficacy Results of Clarity AD Mean change of CDR-SB from baseline at 18 months as the primary endpoint was 1.21 and 1.66 for lecanemab and placebo groups, respectively. Lecanemab treatment resulted in highly statistically significant results, reducing clinical decline on the global cognitive and functional scale, compared with placebo at 18 months by -0.45 (95% Confidence Interval (CI): -0.67, -0.23; P=0.00005), representing a 27% slowing of decline. Starting as early as six months (difference: -0.17 [95% CI: -0.29, -0.05]; P
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. VWM disease is a type of Leukodystrophy. Ella Rose is 1 of 300 in the world diagnosed. Ella, her 12-year-old brother, mom and dad live in Huntersville. She is the only one in NC with VWM. Ella Rose captured by Carrie Howland Photography MOORESVILLE, N.C. – Jan. 18, 2022 – PRLog — While casting for our Matilda Jane, Mommy and Me Runway show coming to LKNFEST on June 11, 2022 at the Charles Mack Citizen Center in Mooresville, NC, there was one Mother/Daughter model application that stopped us in our tracks. “My five-year-old daughter has a rare terminal brain disease and has never walked unassisted. Ella uses her little red walker to get around and has a love for fashion and makeup. She would be honored to do this, and I would love to experience this with her. She is truly a blessing and is my hero. I’m in awe of her daily and she touches the lives of everyone she meets. She’s truly remarkable. If selected, I would just need to make sure she can get her walker through the terrain at your location. Thank you. ❤”, wrote Heather McKee, accompanied by photos of herself and her daughter. Event and show producer, Tammy Domenick and Matilda Jane Representative, Kimberly Sova knew right there that Ella Rose and Heather were going to walk in the Matilda Jane Runway Show and that they wanted to do all they could to make it amazingly special for the entire McKee family. “Time is precious, and we were not going to make them wait to know if they had been cast in the show”, said Tammy Domenick. “Ella Rose and her family face uncertainty daily, and the feeling of not knowing what’s next must be incredibly hard to bear. If I could relieve just an ounce of their wondering, I knew I had to,” added Kimberly Sova. Through more conversations with Heather, we became aware of just how rare Ella Rose’s disease is. Leukodystrophies are a group of rare, progressive, metabolic, genetic diseases that affect the brain, spinal cord and often the peripheral nerves. There are 50 different types of leukodystrophies. Each type of leukodystrophy is caused by a specific gene abnormality that leads to abnormal development or destruction of the white matter (myelin sheath) of the brain. Vanishing White Matter disease is Ella’s type of Leukodystrophy. In layman’s terms, Ella needs a miracle as she was only given a few short years to live. She has a genetic disease that is destroying or will destroy the part of her brain that controls function and doctors cannot tell how rapidly this disease will take control of her tiny little body. Her motor skills, speech, hearing, vision, swallowing, etc., will all slowly begin to deteriorate, with the very raw possibility of ultimately taking Ella’s life. There are only six hospitals (Ella and her family travel to the Children’s Hospital of Philadelphia) On the January 29, 2022, LKNFEST will be livestreaming the announcement of Ella Rose rocking our runway, from our Girls’ Day Out event taking place at the Aloft Mooresville, from 12 pm to 6 pm. We will be presenting Heather and Ella Rose a Gift Basket to brighten their day, along with a special balloon bouquet in Ella Rose’s favorite colors from our sponsor Lakeside Balloons! If anyone would like to contribute a gift item or gift card to the Gift Basket, please email info@lknfest.com; If anyone with a brick-and-mortar location is willing to place a poster in your window, please e-mail info@lknfest.com. If you would like to donate to Ella Rose directly to help offset the weekly medical expenses you may do so through her GoFundMe at https://www.gofundme.com/ We ask everyone to please share Ella’s story on social media. Follow both her Instagram and Facebook @AMiracleForEllaRose. Share. Share. Share. Ella’s doctors strongly encouraged the family to spread the word in hope of more research launched by doctors and pharmaceutical companies looking to find a cure. Any help in making Vanishing White Matter Disease and Leukodystrophy known would be greatly appreciated by Ella’s family. We are so thrilled to show this very special, sweet girl and her family an amazing time on both the January 29, 2022 and at LKNFEST this June; but more importantly to show them that they are not alone in their fight. LKNFEST was created to shine a light on our amazing local businesses and community and we can’t think of a better way for us to show off just how incredible the people here in the Lake Norman and Charlotte area are than supporting this family. For more information on LKNFEST or the Girls’ Day Out, Sip n’ Shop event series, please visit https://www.lknfest.com or email info@lknfest.com.Japan – Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Figure 1: CDR-SB as Primary endpoint change (18 months)
All key secondary endpoints also showed highly statistically significant results compared with placebo (P
For more information, visit www.eisai.com/news/2022/pdf/enews202285pdf.pdf.LKNFEST to Raise Awareness of Vanishing White Matter Disease a Very Rare, Terminal Brain Disease
Ads
